ClinicalTrials.gg
CompletedNCT04385082CanSexUpdated Oct 27, 2026

Cannabis Effects as a Function of Sex

A Phase 1 interventional study of Active Cannabis and Placebo Cannabis in Pain and Abuse, Drug, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of California, Los Angeles · Phase 1, Interventional, and Basic science

How we know

Updated Oct 27, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing cannabis sativa subsp. indica TOP in Pain — 2 open to participants now, 5 under way, none of them phase 3. cannabis sativa subsp. indica TOP · Pain.

Enrollment
Largest of 12
161 · median 31
Started
2021
with 5 others
Phase 1
7 of 12
2 open now
Registered
4th of 12
by date
Lead sponsor
4 of 12
University of California, Los Angeles

Among the 12 studies testing cannabis sativa subsp. indica TOP in Pain, this one has the largest enrollment, is one of 6 that started in 2021, is one of 7 in phase 1, and was the 4th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

2 of the 12 studies testing cannabis sativa subsp. indica TOP in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About cannabis sativa subsp. indica TOP

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing cannabis sativa subsp. indica TOP in Pain, or all of them as a file.
02

Study summary

The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-related effects between men and women

Read the detailed description

The proposed study will compare smoked cannabis's dose-dependent, analgesic and abuse-related effects between men and women and variables that underlie these sex-dependent differences, including pharmacokinetics of THC.

03

Conditions studied

  • Pain
  • Abuse, Drug

Keywords

  • Pain
  • Cannabis
  • THC
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant female aged 21-55 years
  • Report use of cannabis an average of 1-7 days per week
  • Not currently seeking treatment for their cannabis use
  • Urine test positive for recent cannabis use for heavy users
  • No reported adverse effects with cannabis smoking in light users
  • Have a from 18.5 - 34kg/m2.
  • Able to perform all study procedures
  • FEMALES: Currently practicing a non-hormonal effective form of
  • FEMALES: Must be regularly cycling

Exclusion criteria

Exclusion Criteria:

  • Meeting criteria for any substance use disorder other than nicotine, caffeine, or cannabis use disorder
  • Report using other illicit drugs in the prior 4 weeks
  • History or current evidence of severe psychiatric illness or medical condition judged by the study physician and PI to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide .
  • Current use of medical cannabis, prescription analgesics, or any medications that may affect study outcomes
  • Current pain
  • Insensitivity to the cold water stimulus of the Cold Pressor Test
  • FEMALES: using a hormonal
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
161 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Smoked Cannabis (\~0% THC)

    Drug: Placebo Cannabis

  • Experimental
    Low strength cannabis

    Smoked Cannabis (\~4% THC)

    Drug: Active Cannabis

  • Experimental
    Higher strength cannabis

    Smoked Cannabis (\~10% THC)

    Drug: Active Cannabis

Interventions

06

What researchers measure

Primary outcomes

  1. Subject-rated drug effects

    Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).

    Time frame: 5 hours

  2. Analgesia as measured using the Cold Pressor Test

    Peak and average pain threshold and tolerance assessed using the Cold Pressor Test

    Time frame: 5 hours

  3. Pharmacokinetics of THC and metabolites

    Plasma levels of THC, 11-OH-THC, and THCCOOH

    Time frame: 5 hours

Secondary outcomes

  1. Drug reinforcement using the cannabis self-administration task

    Average number of cannabis puffs self-administered as a function of cannabis strength and sex. For this task, up to three 'puffs' of cannabis may be chosen for self-administration during each session.

    Time frame: 5 hours

07

Study locations

1 site
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
08

References and documents

Publications

  • Pabon E, Baglot SL, Eversole A, Fong T, Hampilos K, Hilger A, Lake S, Murray CH, Arout CA, Haney M, Tran A, Torrens A, Piomelli D, Cooper ZD. Cannabis use patterns and perception of acute pain during brief abstinence: sex-dependent associations with circulating cannabinoid levels. Psychopharmacology (Berl). 2026 Apr 21:10.1007/s00213-026-07063-2. doi: 10.1007/s00213-026-07063-2. Online ahead of print. PubMed 42009751 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jul 2026, 60 months.

Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 60 months is above that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Sep 2026 → Jul 2026 and completion Sep 2027 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2020
First posted
May 12, 2020
StartActual
Jul 8, 2021
Primary completionActual
Jul 30, 2026was Sep 2026
CompletionActual
Jul 30, 2026was Sep 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 27, 2026
Primary completion
Sep 1, 2026→Jul 30, 2026 (actual)
Oct 27, 2026
Study completion
Sep 1, 2027→Jul 30, 2026 (actual)
Oct 27, 2026
Enrollment
160 (estimated)→161 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Completed
    Primary completion Sep 1, 2026→Jul 30, 2026 (now actual)
    Study completion Sep 1, 2027→Jul 30, 2026 (now actual)
    Enrollment 160 (estimated)→161 (actual)
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04385082
Responsible party
Ziva D. Cooper, PhD (Associate Professor, University of California, Los Angeles) — Principal investigator
First posted
May 12, 2020
Start date
Jul 8, 2021
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update
Oct 27, 2026

Study contacts

Ziva Cooper, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabis sativa subsp. indica TOP

Start the discussion